VCU-led research highlights semaglutide’s potential for treating fatty liver disease
International study shows drug reverses liver damage in patients.
2025-04-30
(Press-News.org) EMBARGOED FOR RELEASE
5 PM EDT, APRIL 30
CONTACT: A.J. Hostetler
VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Phone: 804-543-8656 (cell)
Email: AJ.Hostetler@vcuhealth.org
VCU-led research highlights semaglutide’s potential for treating fatty liver disease
International study shows drug reverses liver damage in patients.
RICHMOND, Va. (April 30, 2025) – An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a common liver disease that affects millions worldwide.
Led by Arun Sanyal, M.D., of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, and Philip Newsome, Ph.D., of King’s College London, researchers are exploring the potential of semaglutide to treat people with metabolic dysfunction-associated steatohepatitis, or MASH. They reported their results from a phase 3 clinical trial in this week’s New England Journal of Medicine.
“The results from this landmark study across 37 countries provide strong evidence that semaglutide can help patients with MASH by not only improving liver health, but also addressing the underlying metabolic issues that contribute to the disease,” said Sanyal, who is the lead author on the new paper and is also a professor of medicine at the VCU School of Medicine.
An estimated 15 million Americans have the liver disease MASH, which occurs when fat builds up in the liver, leading to inflammation and scarring. Currently, there is only one FDA-approved treatment available, increasing the urgency for effective therapeutic options.
“If approved, this could offer an additional therapeutic option for patients with MASH and fibrosis,” Sanyal added. “This is crucial, given the strong link between MASH and cardiovascular, metabolic, and renal conditions, where semaglutide has already shown established health benefits.”
MASH is closely linked to metabolic risk factors like obesity, type 2 diabetes, and high blood pressure. Over time, MASH can lead to liver fibrosis, cirrhosis, and even liver failure that requires a liver transplant, making it a major public health concern.
Of the 800 participants in the “Effect of Semaglutide in Subjects with Non-cirrhotic Non-alcoholic Steatohepatitis” (ESSENCE) trial, 534 were assigned to take semaglutide and 266 were in a placebo group:
About 63% semaglutide users experienced a reduction in liver inflammation without worsening scarring, compared to only 34% of the placebo group.
Almost 37% of those on semaglutide showed less liver scarring, compared to nearly 23% in the placebo group.
About a third of semaglutide users achieved both inflammation reduction and scarring improvement, more than double compared to those taking the placebo.
The drug also helped participants with weight loss, improved liver markers, and boosted overall heart health – with no major differences in serious side effects compared to those not taking it.
The ultimate goal for researchers in the ESSENCE trial is to find the right balance of semaglutide to resolve the damage caused by the fat buildup in the liver (steatohepatitis) while at the same time improve the scarring (fibrosis). Both are crucial for improving liver health in patients with MASH.
Semaglutide is a GLP-1 receptor agonist medication. Wegovy and Ozempic are brand names for semaglutide and are approved to promote weight loss, improve blood sugar control, and enhance metabolic health. Sanyal and other researchers are studying several GLP-1 receptor agonists and related drugs as potential treatments that might help halt, improve or even reverse the damage caused by MASH.
“The ESSENCE data may represent key findings for patients in the treatment of MASH, which is estimated to affect about one in 20 adults in the U.S.,” Sanyal said. “By treating both liver disease and its metabolic causes, semaglutide offers a promising new approach for millions of patients.”
The clinical trial involved participants with moderate to advanced liver scarring who were treated for 72 weeks with either 2.4 milligrams weekly injections of semaglutide or a placebo. Most participants tolerated semaglutide well. Nearly 90% of participants remained on the medication after 72 weeks. The most common side effects were mild digestive issues, such as nausea.
In the second part of this clinical trial, researchers led by Sanyal will follow nearly 1,200 participants from 37 countries for up to five years to gather data on semaglutide’s impact on long-term liver complications.
Semaglutide, manufactured by Novo Nordisk, belongs to a class of drugs called GLP-1 receptor agonists. Ozempic and Wegovy are brand names for semaglutide and are approved by the U.S. Food and Drug Administration for different conditions.
Semaglutide is not approved to treat MASH in the U.S. Pharmaceutical maker Novo Nordisk has said it plans to seek regulatory approval for its use in treating liver disease sometime this year.
###
About VCU and VCU Health
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 28,000 students in more than 200 degree and certificate programs in the arts, sciences and humanities across VCU’s 12 schools and three colleges. The VCU Health brand represents the VCU health sciences academic programs, the VCU Massey Comprehensive Cancer Center and the VCU Health System, which comprises VCU Medical Center (the only academic medical center in the region), Community Memorial Hospital, Tappahannock Hospital, Children’s Hospital of Richmond at VCU, and MCV Physicians. The clinical enterprise includes a collaboration with Sheltering Arms Institute for physical rehabilitation services. For more, please visit vcu.edu and vcuhealth.org.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-04-30
MINNEAPOLIS — People whose biological age is higher than their chronological age may be more likely to develop dementia than people whose biological age matches or is lower than their chronological age, according to a study published on April 30, 2025, online in Neurology®, the medical journal of the American Academy of Neurology. Biological age is based on biomarkers of aging such as lung function, blood pressure and cholesterol.
The study does not prove that advanced biological age causes dementia; it only shows an association.
“With the rising impact of dementia around the world, identifying risk factors and implementing preventive ...
2025-04-30
Researchers with the University of Calgary and the Chinese University of Hong Kong (CUHK) led an international collaboration that found inflammatory bowel disease (IBD) progresses through four predictable epidemiological stages as it spreads globally. Published in Nature, the study forecasts a major rise in IBD prevalence in Canada by 2045. Researchers say pinpointing where each region sits on the trajectory gives health-care systems a clear roadmap for anticipating and managing IBD today and in the decades to follow.
“Our analysis draws on a century worth of historical epidemiologic data. The findings enable health authorities ...
2025-04-30
The Ecological Society of America is pleased to announce its 2025 Fellows. The Society’s fellowship program recognizes the many ways in which its members contribute to ecological research, communication, education, management and policy. This year, the ESA Governing Board has confirmed eight new Fellows and ten new Early Career Fellows.
Fellows are members who have made outstanding contributions to a wide range of fields served by ESA, including, but not restricted to, those that advance or apply ecological knowledge in academics, ...
2025-04-30
Critically endangered axolotls bred in captivity appear able to survive release into both artificial and restored Mexican wetlands, but may need specific temperatures to thrive
Article URL: https://plos.io/3RSL1bu
Article title: Movement ecology of captive-bred axolotls in restored and artificial wetlands: Conservation insights for amphibian reintroductions and translocations
Author countries: Mexico
Funding: This project was funded by UNAM PAPIIT No. 705 IV200117 and IV210117 Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (PAPIIT-IV200117) ...
2025-04-30
Tunnel vision during planning can lead us to neglect negative consequences, but this cognitive bias can be addressed by simply prompting people to explicitly consider them
Article URL: https://plos.io/42yZBtL
Article title: Side effects may include: Consequence neglect in generating solutions
Author countries: U.S.
Funding: The author(s) received no specific funding for this work. END ...
2025-04-30
Human populations need at least 2.7 children per woman – a much higher fertility rate than previously believed – to reliably avoid long-term extinction, according to a new study published April 30, 2025 in the open-access journal PLOS One by Takuya Okabe of Shizuoka University, Japan, and colleagues.
While a fertility rate of 2.1 children per woman is often considered the replacement level needed to sustain a population, this figure doesn’t account for random differences in how many children people have – as well as mortality ...
2025-04-30
Researchers at Mass General Brigham have identified new biomarkers for tinnitus by measuring pupil dilation and subtle facial movements that correlate with the level of distress caused by the disorder. Published in Science Translational Medicine, the findings could lead to placebo-controlled treatment studies that have largely been not feasible due to lack of objective measures.
“Imagine if cancer severity were determined by giving patients a questionnaire – this is the state of affairs for some common neurological disorders like tinnitus,” said corresponding author Daniel Polley, ...
2025-04-30
An AI tool has made a step forward in translating the language proteins use to dictate whether they form sticky clumps similar to those linked to Alzheimer’s Disease and around fifty other types of human disease. In a departure from typical “black-box” AI models, the new tool, CANYA, was designed to be able to explain its decisions, revealing the specific chemical patterns that drive or prevent harmful protein folding.
The discovery, published today in the journal Science Advances, was possible thanks to the largest-ever dataset on protein aggregation created to date. The study gives new insights about the molecular mechanisms underpinning sticky proteins, which are ...
2025-04-30
Mounting evidence supports ayahuasca’s potential to improve mental health, but its long-term effects are shaped by both individual mental health history and the context in which the psychedelic is used, according to a study published on April 30, 2025 in the open-access journal PLOS Mental Health by Óscar Andión from Research Sherpas, Spain; José Carlos Bouso from the International Centre for Ethnobotanical Education, Research, and Services (ICEERS) and the University of Rovira i Virgili, Spain; Daniel Perkins from the University of Melbourne and Swinburne University; and colleagues.
Ayahuasca, a psychedelic medicine traditionally ...
2025-04-30
National-level policies can reduce the impact of antibiotic resistance across diverse countries, according to a study published April 30, 2025 in the open-access journal PLOS Global Public Health by Peter Søgaard Jørgensen from Stockholm University and the Royal Swedish Academy of Sciences, Sweden, and colleagues.
Antibiotic resistance is a major public health concern, contributing to 1.27 million deaths per year. In 2016, countries around the world committed to developing and implementing national action plans to combat antibiotic resistance. These plans have been criticized ...
LAST 30 PRESS RELEASES:
[Press-News.org] VCU-led research highlights semaglutide’s potential for treating fatty liver disease
International study shows drug reverses liver damage in patients.
